Context:

Sun Pharmaceutical Industries has initiated a nationwide recall of several lots of lisdexamfetamine dimesylate capsules, a generic version of Vyvanse, due to failed dissolution specifications that could affect the medication's efficacy. Classified by the FDA as a Class II recall, the action indicates a low risk of serious health consequences, though patients may experience temporary or reversible effects. The recall, announced on October 30, follows an initiation date of October 28, prompting a recommendation for patients to check their medications and consult healthcare providers for replacements or refunds. Users are advised against abruptly stopping their ADHD medication to avoid withdrawal symptoms. Future actions will likely include enhanced monitoring and guidance from health authorities.

Dive Deeper:

• The recall affects multiple dosages of lisdexamfetamine dimesylate capsules, including 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg, all in 100-count bottles.

• Lot numbers for the recalled capsules include AD42468, AD48705, AD42469, AD48707, and others, with expiration dates ranging from February to May 2026.

• The FDA's Class II classification means that while serious health risks are low, the recalled medication could lead to temporary adverse health effects.

• Sun Pharmaceutical did not release detailed instructions for users, emphasizing the importance of not discontinuing the medication without medical advice.

• Patients are encouraged to contact their healthcare providers or pharmacies for guidance on obtaining replacements or refunds for the recalled medications.